Utility of intravenous immune globulin in kidney transplantation: Efficacy, safety, and cost implications

American Journal of Transplantation

Volumn 3, Issue 6, 2003, Pages 653-664

  Jordan, Stanley ^a   Cunningham Rundles, Charlotte ^b   McEwanc, Robert ^c  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c MEDBANK of Maryland Inc   (United States)

Author keywords

IVIG; Kidney transplantation; Panel reactive antibodies

Indexed keywords

ADRENALIN; ALBUMIN; ANALGESIC AGENT; CARIMUNE; CORTICOSTEROID; CYTOMEGALOVIRUS ANTIBODY; DACLIZUMAB; DIAZEPAM; DIPHENHYDRAMINE; GAMIMINE N; HLA ANTIBODY; IBUPROFEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PENICILLIN G; PREDNISONE; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ANAPHYLAXIS; ANTIINFLAMMATORY ACTIVITY; ASEPTIC MENINGITIS; AUTOIMMUNE DISEASE; BRAIN VASOSPASM; CENTRAL RETINA VEIN OCCLUSION; CHILL; CLINICAL TRIAL; COMPLEMENT ACTIVATION; CYTOKINE PRODUCTION; DEEP VEIN THROMBOSIS; DESENSITIZATION; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED DISEASE; DRUG INFUSION; DRUG MECHANISM; DRUG SAFETY; FATIGUE; FEVER; GRAFT REJECTION; GRAFT SURVIVAL; HEADACHE; HEART INFARCTION; HUMAN; HYPOTENSION; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOPHARMACOLOGY; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY DISEASE; KIDNEY TRANSPLANTATION; LUNG EMBOLISM; MUSCLE SPASM; MYALGIA; NAUSEA; NOSE CONGESTION; PETECHIA; PLASMAPHERESIS; POSTOPERATIVE CARE; PREOPERATIVE TREATMENT; PRURITUS; SHORT SURVEY; SKIN MANIFESTATION; STROKE; SWEATING; T LYMPHOCYTE; THORAX PAIN; THROMBOSIS; TREATMENT OUTCOME; URTICARIA; VASCULITIS; VERTIGO; WHEEZING;

COMPLEMENT SYSTEM PROTEINS; GRAFT REJECTION; HLA ANTIGENS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; KIDNEY TRANSPLANTATION; LYMPHOCYTES;

EID: 0037869387     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-6143.2003.00121.x     Document Type: Short Survey

References (67)

1. UNOS. Patient Data Source website: http://www.patients.unos.org/tpd/. Accessed August 6 2002.
2. Cecka JM. The UNOS, Scientific Renal Transplant Registry 2000. Clin Transpl 2000; 1-18.
3. Patel R, Terasaki P. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969; 280: 735-739.
4. Tyan DB, Li VA, Czer L, Trento A, Jordan SC. Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatable organ. Transplantation 1994; 57: 553-562.
5. Rudich S, Hanson J, Cibrik D, Leichtman A, Kaplan B. Effect of waiting time on renal transplant outcomes. Kidney Int 2000; 58: 1311-1317.
6. Mange KC, Joffe MM, Feldman HI. Effect of the use or nonuse of long-term dialysis on the subsequent survival of renal transplants from living donors. N Engl J Med 2001; 344: 726-731.
7. Shaharabani E, Bar-Nathan N, Shmueli D et al. Use of intravenous immunoglobulin in organ transplantation for noninfectious indications. Transplant Proc 1997; 29: 3058-3059.
8. Sivasai KSR, Mohanakumar T, Phelan D, Martin S, Anstey ME, Brennan DC. Cytomegalovirus immune globulin intravenous (human) administration modulates immune response to alloantigens in sensitized renal transplant candidates. Clin Exp Immunol 2000; 199: 559-565.
9. Wadstrom J, Gannedahl G, Bersztel A, Bengtsson M, Nattorp K, Mulec H. Successful kidney transplantation after suppression of HLA alloantibodies with intravenous immunoglobulin in a highly sensitized patient. Transplant Proc 1995; 27: 3463-3464.
10. Dwyer JM. Manipulating the immune system with immune globulin. N Engl J Med 1992; 326: 107-116.
11. Ronda N, Kaveri Kazatchkine MD. Treatment of autoimmune disease with normal immunoglobulin through manipulation of the idiotypic network. Clin Exp Immunol 1993; 93: 14-15.
12. Kaveri SV, Dietrich G, Hurez V, Kazatchkine MD et al. Intravenous immunoglobulins (II/Ig) in the treatment of autoimmune disease. Clin Exp Immunol 1991; 86: 192-198.
13. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345: 747-755.
14. Wassmuth R, Hauser IA, Schuler K et al. Preparations on HLA-alloantibodies in vitro. Transplantation 2001; 71: 1436-1437.
15. Glotz D, Haymann JP, Naiudet P, Lang P, Druet P, Bariety J. Successful kidney transplantation of immunized patients after desensitization with normal human polyclonal immunoglobulins. Transplant Proc 1995; 27: 1038-1039.
16. Morell A. Various immunoglobulin preparations for intravenous use. Vox Sang 1986; 51 (Suppl. 2): s44-s49.
17. Glotz D, Antione C, Haymann JP, Julia P, Duboust A, Bariety J. Intravenous immunoglobulins and kidney transplant inpatients with anti-HLA antibodies. Adv Neurol 2000; 30: 221-233.
18. Gelfand EW. Antibody-directed therapy, past, present, and future. J Allergy Clin Immunol 2001; 108 (Suppl. 4): s111-s116.
19. Francois A, Menoyo-Calonge V, Bariety J et al. Suppression of HLA-specific alloantibodies by high-dose intravenous immunoglobulins (IVIG). Transplantation 1993; 56: 335-337.
20. Admon D, Chen G, Fishbein MC et al. Post-transplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation 1998; 66: 800-805.
21. Nielson H. Immunoglobulin preparations for intravenous administration: a review of their biologic activities and comparison of various preparation methods. Allergy 1994; 49: 69-73.
22. Schwartz SA. Intravenous immunoglobulin treatment of immunodeficiency disorders. Pediatr Clin North Am 2000; 47: 1355-1369.
23. Toyoda M, Zhang X, Petrosian A, Wachs K, Mougdit A, Jordan SC. Modulation of immunoglobulin production and cytokine mRNA expression in peripheral blood mononuclear cells by IVIG. J Clin Immunol 1994; 14: 178-189.
24. Andersson U, Bjork L, Skansen-Saphir U, Andersson J. Pooled human IgG modulates cytokine production in lymphocytes and monocytes. Immunol Rev 1994; 139: 21-42.
25. Daeron M. Fc receptor biology. Annu Rev Immunol 1997; 15: 203-234.
26. Bussel JB. Modulation of Fc receptor clearance and antiplatelet antibodies as a consequence of intravenous immune globulin infusion in patients with immune thrombocytopenic purpura. J Allergy Clin Immunol 1989; 84: 566-578.
27. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001; 291: 484-486.
28. Toyoda M, Pao A, Petrosian A, Jordan SC. Pooled human gammaglobulin modulates surface molecule expression and induces apoptosis in human B cells. Am J Transplant 2003; 3: 156-166.
29. Poe JC, Hasegawa M, Tedder TFCD, 19 CD, 21 CD, 22. multifaceted response regulators of B lymphocyte signal transduction. Int Rev Immunol 2001; 20: 739-762.
30. Jordan SC, Vo AA, Bunnapradist S, Tyan D. IVIG inhibits crossmatch (CMX) positivity and allows successful transplantation in living donor and cadaver transplant recipients. Transplantation (submitted).
31. Lutz HU, Stammler P, Jelezarova E, Nater M, Spath PJ. High doses of immunoglobulin G attenuate immune aggregate-mediated complement activation by enhancing physiologic cleavage of C3b in C3bn-IgG complexes. Blood 1996; 88: 184-193.
32. Vivas CA, Hakala TR, Jain A et al. Reversal of steroid- and antilymphocyte antibody-resistant rejection using intravenous immunoglobulin (IVIG) in renal transplant recipients. Transplantation 2001; 72: 419-422.
33. Casadei D, Rial M, Argento J, Goldberg J, Raimondi E. Preliminary results from a randomized and prospective study of high-dose immunoglobulin versus monoclonal antibody in the rescue of steroid-resistant rejections. Transplant Proc 1998; 30: 2164.
34. Lindman BJ, Bollinger RR, Frank MM et al. Immunoglobulin prevents complement-mediated hyperacute rejection in swineto-primate xenotransplantation. J Clin Invest 1995; 96: 2404-2412.
35. Pratt JR, Basheer SA, Sacks SH. Local synthesis of complement component C3 regulates acute renal transplant rejection. Nature Med 2002; 8: 582-587.
36. Ballow M. Mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory diseases. J Allergy Clin Immunol 1997; 100: 151-157.
37. Lam L, Whitsett C, McNicholl J, Hodge T, Hooper J. Immunologically active proteins in intravenous immunoglobulin [letter]. Lancet 1993; 342: 678.
38. Blasczyk R, Westhoff U, Gross-Wilde H. Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations. Lancet 1993; 341: 789-790.
39. White WB, Desbonnet CR, Ballow M. Immunoregulatory effects of intravenous immune serum globulin therapy in common variable hypogammaglobinemia. Am J Med 1987; 83: 431-436.
40. Toyoda M. Intravenous gammaglobulin (IVIg) inhibits the mixed lymphocyte reaction (MLR). Hum Immunol 1993; 37 (Suppl. 1): 114.
41. Marchalonis JJ, Kaymaz H, Dedeoglu F, Schlutter SF, Yocum DE, Edmundson, AB. Human autoantibodies reactive with synthetic autoantigens from T-cell receptor β chain. Proc Natl Acad Sci U S A 1992; 89: 3325-3329.
42. Toyoda M, Zhang X, Petrosian A, Wachs K, Mougdil A, Jordan SC. Inhibition of allospecific responses in the mixed lymphocyte reaction by pooled human gamma globulin. Transplant Immunol 1994; 2: 337-341.
43. Abe Y, Horiuchi A, Miyake M, Kimura S. Anti-cytokine nature of natural human immunoglobulin: one possible mechanism of the clinical effect of intravenous immunoglobulin therapy. Immunol Rev 1994; 139: 5-19.
44. Shimozato T, Iwata M, Kawada H, T'amura N. Human immunoglobulin preparation for intravenous use induces elevation of cellular cyclic adenosine 3′: 5′-monophosphate levels, resulting in suppression of tumour necrosis factor alpha and interleukin-1 production. Immunology 1991; 72: 497-501.
45. Amran D, Renz H, Lack G, Bradley K, Gelfand EW. Suppression of cytokine-dependent human T-cell proliferation by intravenous immunoglobulin. Clin Immunol Immunopathol 1994; 73: 180-186.
46. Dinarello C. Is there a role for interleukin-1 blockade in IVIG therapy. Immunol Rev 1994; 139: 173-188.
47. Arend WP, Leung DYM. IgG induction of I L-1 receptor antagonist production by human monocytes. Immunol Rev 1996; 139: 71.
48. Golberg JC, Argento JA, Greco G et al. A randomized and prospective study comparing treatment with high-dose intravenous immunoglobulin with monoclonal antibodies for rescue of kidney grafts with steroid-resistant rejection. Transplantation 2001; 71: 53-58.
49. Leffell MS, King KE, Burdick J et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000; 70: 887-895.
50. Schweitzer EJ, Wilson JS, Fernandez-Vina M et al. A high panelreactive antibody rescue protocol for cross-match-positive live donor kidney transplants. Transplantation; 200 (70): 1531-1536.
51. Suberbielle-Boissel C, Boudjeltia S, Fraoui R et al. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins. Am J Trans 2002; 2: 758-760.
52. Jordan SC, Vo AA, Bunnapradist S, Tyan D. IVIG inhibits crossmatch (CMX) positivity and allows successful transplantation in living donor and cadaver transplant recipients [abstract]. Am J Trans 2002; 2 (Suppl. 3): 867.
53. Buckley RH, Burks W, Good RA et al. Multicenter crossover comparison of the safety and efficacy of Intraglobulin-F with Gamimune-N, Sandoglobulin, and Gammagard in patients with primary immunodeficiency diseases. J Clin Immunol 1997; 17: 21-28.
54. Bagdasarian A, Tonetta S, Harel W, Mamidi R, Uemura Y. IVIG adverse reactions: potential role of cytokines and vasoactive substances. Vox Sang 1998; 74: 74-82.
55. Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med 1994; 121: 259-262.
56. Burks AW, Sampson HA, Buckley RH. Anaphylactic reactions after gammaglobulin administration in patients with hypogammaglobulinemia. Detection of IgE antibodies to IgA. N Engl J Med 1986; 314: 560-564.
57. Sandler SG, Mallory D, Malamut D, Eckrich R. IgA anaphylactic transfusion reactions. Transfus Med Rev 1995; 9: 1-8.
58. Laschinger C, Shepherd FA, Naylor DH. Anti-IgA-mediated transfusion reactions in Canada. Can Med Assoc J 1984; 130: 141-144.
59. Rault R, Pirano B, Johnston JR, Oral A. Pulmonary and renal toxicity of intravenous immunoglobulin. Clin Nephrol 1991; 36: 83-86.
60. Winward DB, Brophy MT. Acute renal failure after administration of intravenous immunoglobulin: a review of literature and case report. Pharmacotherapy 1995; 15: 765-772.
61. Cantu TG, Hoehn-Saric EW, Burgess KM, Racusen L, Scheel PJ. Acute renal failure with immunoglobulin therapy. Am J Kidney Dis 1995; 25: 228-234.
62. Gupta N, Ahmed I, Nissel-Horowitz S, Patel D, Mehrotra B. Intravenous gammglobulin-associated acute renal failure. Am J Hematol 2001; 66: 151-152.
63. Ahsan N, Wiegand LA, Abendroth CS, Manning EC. Acute renal failure following immunoglobulin therapy. Am J Nephrol 1996; 16: 532-536.
64. Anonymous. Renal insuffiency and failure associated with immune globulin intravenous therapy- United States 1985-98. MMWR Weekly 1999; 48: 518.
65. FDA. http:/www.fda.gov/medwatch/SAFETY/2002/baxter_igiv.htm. Accessed September 11, 2002.
66. UHC Services Corporation. Technology Assessment: Intravenous Immunoglobulin Preparation. Oakbrook, IL: University Health Consortium, 1995.
67. USRDS Annual Report. http://www.usrds.org/adr.htm. Accessed August 6, 2002.